Summary of TRANZYME INC - Yahoo! Finance

Item 7.01 Regulation FD Disclosure.

On November 28, 2012, Tranzyme, Inc. (the "Company") participated in the 24th Annual Piper Jaffray Healthcare Conference in New York, New York, and held one-on-one discussions with investors using defined presentation materials. A copy of the Company's presentation materials has been posted to the Company's website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibits, is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This Current Report on Form 8-K and the presentations include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the progress and timing of clinical trials, the safety and efficacy of the Company's product candidates, its collaborators, and estimates of the potential markets for the Company's product candidates. Typically, these statements contain words such as "believe", "anticipate", "plan", "intend", and similar expressions. These and other forward-looking statements speak only as of the date of the 8-K and the presentations and are subject to substantial risks and uncertainties and other important factors that may cause the Company's actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by forward-looking statements. Additional risks and uncertainties are described more fully in the Company's Form 10-Q for the quarter ended September 30, 2012 filed on November 9, 2012 and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any of the forward-looking statements except as required by law.